WO1999026942A1 - 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique - Google Patents

5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique Download PDF

Info

Publication number
WO1999026942A1
WO1999026942A1 PCT/US1998/024694 US9824694W WO9926942A1 WO 1999026942 A1 WO1999026942 A1 WO 1999026942A1 US 9824694 W US9824694 W US 9824694W WO 9926942 A1 WO9926942 A1 WO 9926942A1
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
hydrogen
group
cyano
halo
Prior art date
Application number
PCT/US1998/024694
Other languages
English (en)
Other versions
WO1999026942A8 (fr
Inventor
Thomas Lee Cupps
Sophie Lee Bogdan
Nicholas Nikolaides
Sheri Ann Gilbert
Michael Gazda
Roy Lee Martin Dobson
Charles Andrew Cruze, Iii
Original Assignee
The Procter & Gamble Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT98959512T priority Critical patent/ATE271048T1/de
Priority to EP98959512A priority patent/EP1037887B1/fr
Application filed by The Procter & Gamble Company filed Critical The Procter & Gamble Company
Priority to NZ504707A priority patent/NZ504707A/xx
Priority to AU15299/99A priority patent/AU741774B2/en
Priority to DE69825075T priority patent/DE69825075T2/de
Priority to JP2000522100A priority patent/JP2001524478A/ja
Priority to IL13630398A priority patent/IL136303A/en
Priority to HU0101469A priority patent/HUP0101469A3/hu
Priority to BR9815017-0A priority patent/BR9815017A/pt
Priority to SK779-2000A priority patent/SK7792000A3/sk
Priority to US09/554,698 priority patent/US6486190B1/en
Priority to KR1020007005675A priority patent/KR20010032435A/ko
Priority to CA002311344A priority patent/CA2311344C/fr
Publication of WO1999026942A1 publication Critical patent/WO1999026942A1/fr
Priority to NO20002655A priority patent/NO20002655L/no
Publication of WO1999026942A8 publication Critical patent/WO1999026942A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • R2, R3, R4 or R5 is other than hydrogen or fluorine;
  • R1 is methyl and both R2 and R5 are hydrogen, R3 is other than methyl or halo;
  • R3 is cyano, R1 is methyl;
  • R5 is hydrogen, methyl, amino, methoxy, hydroxy, cyano or halo.
  • Preferred R5 is hydrogen, methyl, or halo.
  • at least one of R2, R3, R4, and R5 is other than hydrogen or fluorine.
  • R1 is methyl and both R2 and R5 are hydrogen, then R3 is other than methyl or halo.
  • R3 is cyano, R1 is methyl.
  • acids-addition salts include, but at not limited to hydrochloride, hydrobromide, hydroiodide, sulfate, hydrogensulfate, acetate, trifluoroacetate, nitrate, maleate, citrate, fumarate, formate, stearate, succinate, mallate, malonate, adipate, glutarate, lactate, propionate, butyrate, tartrate, methanesulfonate, trifluoromethanesulfonate, p-toluenesulfonate, dodecyl sulfate, cyclohexanesulfamate, and the like.
  • the compounds of the present invention are useful in treating many medical disorders, including for example, respiratory disorders, ocular disorders, gastrointestinal disorders, disorders associated with sympathetic nervous system activity, migraine, peripheral pain, and disorders where vasoconstriction would provide a benefit.
  • One tablet is swallowed by a patient with nasal congestion.
  • the congestion is substantially diminished.
  • One tablet is placed under the tongue of a patient with nasal congestion and allowed to dissolve. The congestion is rapidly and substantially diminished.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Cette invention concerne des composés présentant une structure correspondant à la formule (I), dans laquelle: (a) R1 représente alkyle; (b) R2 est sélectionné dans le groupe formé par: hydrogène, alkyle, méthoxy, cyano et halo; (c) R3 est sélectionné dans le groupe formé par: hydrogène, méthyle, hydroxy, cyano et halo; (d) R4 est sélectionné dans le groupe formé par: hydrogène, méthyle, éthyle et isopropyle; R5 est sélectionné dans le groupe formé par: hydrogène, méthyle, amino, méthoxy, hydroxy, cyano et halo; (f) à condition qu'au moins un des constituants R2, R3, R4 ou R5 ne représente pas hydrogène ou fluor; (g) à condition que lorsque R1 représente méthyle et que R2 et R5 représentent tous les deux hydrogène R3 ne représente pas méthyle ou halo; (h) à condition que lorsque R3 représente cyano, R1 représente méthyle. Cette invention concerne également n'importe quel tautomère correspondant à cette structure, ou un sel pharmaceutiquement acceptable ou bien encore un ester biohydrolysable, un amide ou un imide de ce dernier. Les composés de cette invention sont des composés sélectifs du type alpha-adrénergique à action périphérique qui réduisent l'activité du SNC et qui ne peuvent être transformés par le métabolisme en composés indésirables.
PCT/US1998/024694 1997-04-15 1998-11-20 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique WO1999026942A1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
BR9815017-0A BR9815017A (pt) 1997-11-24 1998-11-20 Derivados de 5-(2-imidazolinilamino)-benzimidazol, sua preparação e seu uso como agonistas de alfa-adrenorreceptores com estabilidade metabólica aperfeiçoada
HU0101469A HUP0101469A3 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability
NZ504707A NZ504707A (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
EP98959512A EP1037887B1 (fr) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique
DE69825075T DE69825075T2 (de) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität
JP2000522100A JP2001524478A (ja) 1997-11-24 1998-11-20 ５−（２−イミダゾリニルアミノ）−ベンゾイミダゾール誘導体類、それらの調製および改良された代謝安定性を有するアルファアドレナリン受容体作動薬としてのそれらの使用
SK779-2000A SK7792000A3 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as alpha-adrenoceptor agonists with improved metabolic stability
AT98959512T ATE271048T1 (de) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazol derivate, deren herstellung und deren verwendung als .alpha.-adrenoceptor agonisten mit verbesserter metabolischer stabilität
AU15299/99A AU741774B2 (en) 1997-04-15 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
IL13630398A IL136303A (en) 1997-11-24 1998-11-20 History -5 (-2 Imidazolinylamino) - Banimidazole, preparation and use as an α-adororeceptor agonists
US09/554,698 US6486190B1 (en) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
KR1020007005675A KR20010032435A (ko) 1997-11-24 1998-11-20 5-(2-이미다졸리닐아미노)벤즈이미다졸 유도체, 그의 제조및 대사 안정성이 개선된 알파-아드레날린수용체아고니스트로서의 그의 용도
CA002311344A CA2311344C (fr) 1997-11-24 1998-11-20 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleurestabilite metabolique
NO20002655A NO20002655L (no) 1997-11-24 2000-05-24 5-(2-imidazolinylamino) -benzimidazol derivater, fremstilling og anvendelse derav som <alfa>-adrenoceptoragonister med forbedret metabolisk stabilitet

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6676797P 1997-11-24 1997-11-24
US60/066,767 1997-11-24
US6670097P 1997-11-25 1997-11-25
US60/066,700 1997-11-25

Publications (2)

Publication Number Publication Date
WO1999026942A1 true WO1999026942A1 (fr) 1999-06-03
WO1999026942A8 WO1999026942A8 (fr) 2000-08-03

Family

ID=26747058

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/024694 WO1999026942A1 (fr) 1997-04-15 1998-11-20 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d'utilisation de ces derniers en tant qu'agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique

Country Status (23)

Country Link
US (1) US6486190B1 (fr)
EP (1) EP1037887B1 (fr)
JP (1) JP2001524478A (fr)
KR (1) KR20010032435A (fr)
CN (1) CN1284073A (fr)
AT (1) ATE271048T1 (fr)
BR (1) BR9815017A (fr)
CA (1) CA2311344C (fr)
CO (1) CO4970802A1 (fr)
DE (1) DE69825075T2 (fr)
ES (1) ES2223143T3 (fr)
HU (1) HUP0101469A3 (fr)
IL (1) IL136303A (fr)
IN (1) IN190809B (fr)
NO (1) NO20002655L (fr)
NZ (1) NZ504707A (fr)
PE (1) PE133699A1 (fr)
PL (1) PL340711A1 (fr)
RU (1) RU2193562C2 (fr)
SK (1) SK7792000A3 (fr)
TR (1) TR200002242T2 (fr)
TW (1) TW505642B (fr)
WO (1) WO1999026942A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074279A1 (fr) * 2003-02-20 2004-09-02 The Board Of Regents Of The University Of Nebraska Procedes de fabrication de 6-[(4,5-dihydro-1h-imidazol-2-yl)amino-]-7-methyl-1h-benzimidazole-4-carbonitrile et forme preferee d'un sel de celui-ci
WO2004074234A1 (fr) * 2003-02-20 2004-09-02 Lonza Ag Procede de preparation de formamides n-substitutes
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7456183B2 (en) 2001-04-09 2008-11-25 Novartis Vaccines And Diagnostics, Inc. Guanidino compounds
US8420688B2 (en) 2004-01-22 2013-04-16 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2015073736A1 (fr) * 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Méthodes et compositions de traitement du tdah
EP2481412B1 (fr) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Composés, formulations et procédés pour traiter ou prévenir les troubles inflammatoires de la peau

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
JP2015517980A (ja) * 2012-02-27 2015-06-25 アイ・セラピーズ・エル・エル・シー 片頭痛の治療のための組成物および方法
MX2018006575A (es) * 2015-11-30 2018-12-06 Novus Therapeutics Inc Composiciones y metodos para profilaxis otologica y tratamiento.
EA030197B1 (ru) * 2016-03-22 2018-07-31 Общество С Ограниченной Ответственностью "Рубикон" Таблетированная форма противовирусного лекарственного средства
JP7163014B2 (ja) * 2016-10-31 2022-10-31 エスエス製薬株式会社 感冒薬

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016685A1 (fr) * 1993-12-17 1995-06-22 The Procter & Gamble Company Derives de 5-(2-imidazolinylamino)benzimidazole, leur preparation et leur utilisation en tant qu'agonistes de l'adrenocepteur alpha-2
WO1996004270A1 (fr) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Nouveaux derives de benzimidazole
WO1998046595A1 (fr) * 1997-04-15 1998-10-22 The Procter & Gamble Company Composes de 5-(2-imidazolinylamino)benzimidazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4036976A (en) 1973-04-05 1977-07-19 Sandoz, Inc. Substituted imidazolinylamino-indazoles
US4217356A (en) 1975-08-22 1980-08-12 Sandoz Ltd. 2-Imidazolinylamino-2,1,3-benzothiadiazoles
US4398028A (en) 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
EP0086428B1 (fr) 1979-08-23 1987-07-29 Beecham Group Plc Composition vétérinaire anti-diarrhée, sa préparation et dispositif pour le dosage oral la contenant
WO1982000824A1 (fr) 1980-09-05 1982-03-18 Geissmann F Derives 1h et 2h de l'indazol et medicaments les renfermant
FR2638356A1 (fr) 1988-10-28 1990-05-04 Anben Nouveaux derives de la 2-arylimino-imidazolidine pour diminuer la pression intra-oculaire et traiter le glaucome
US5281591A (en) 1989-05-22 1994-01-25 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5180721A (en) 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
US5231096A (en) 1989-10-12 1993-07-27 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5021416A (en) 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5091528A (en) 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995016685A1 (fr) * 1993-12-17 1995-06-22 The Procter & Gamble Company Derives de 5-(2-imidazolinylamino)benzimidazole, leur preparation et leur utilisation en tant qu'agonistes de l'adrenocepteur alpha-2
WO1996004270A1 (fr) * 1994-08-04 1996-02-15 Synaptic Pharmaceutical Corporation Nouveaux derives de benzimidazole
WO1998046595A1 (fr) * 1997-04-15 1998-10-22 The Procter & Gamble Company Composes de 5-(2-imidazolinylamino)benzimidazole utiles en tant qu'agonistes de l'adrenorecepteur alpha-2

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456183B2 (en) 2001-04-09 2008-11-25 Novartis Vaccines And Diagnostics, Inc. Guanidino compounds
WO2004074279A1 (fr) * 2003-02-20 2004-09-02 The Board Of Regents Of The University Of Nebraska Procedes de fabrication de 6-[(4,5-dihydro-1h-imidazol-2-yl)amino-]-7-methyl-1h-benzimidazole-4-carbonitrile et forme preferee d'un sel de celui-ci
WO2004074234A1 (fr) * 2003-02-20 2004-09-02 Lonza Ag Procede de preparation de formamides n-substitutes
US7304084B2 (en) 2003-02-20 2007-12-04 The Board Of Regents Of The University Of Nebraska 6-[(4,5-Dihydro-1H-imidazol-2-yl)amino]-7-methyl-1H-benzimidazole-4-carbonitrile and its preferred salt
EP1953146A1 (fr) 2003-02-20 2008-08-06 The Board of Regents of the University of Nebraska Procédé de fabrication de 6-[(4,5-Dihydro-1H-Imidazol-2-yl) Amino-]-7-Methyl-1H-Benzimidazole-4-Carbonitrile et sa formule de sel préférée
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US8420688B2 (en) 2004-01-22 2013-04-16 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US8815929B2 (en) 2004-01-22 2014-08-26 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US8877793B2 (en) 2004-01-22 2014-11-04 Allergan, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
EP2481412B1 (fr) * 2004-05-25 2017-09-27 Galderma Pharma S.A. Composés, formulations et procédés pour traiter ou prévenir les troubles inflammatoires de la peau
WO2015073736A1 (fr) * 2013-11-13 2015-05-21 Arbor Pharmaceuticals, Llc Méthodes et compositions de traitement du tdah

Also Published As

Publication number Publication date
WO1999026942A8 (fr) 2000-08-03
DE69825075T2 (de) 2005-08-25
IN190809B (fr) 2003-08-23
TR200002242T2 (tr) 2000-11-21
BR9815017A (pt) 2001-09-11
RU2193562C2 (ru) 2002-11-27
CA2311344A1 (fr) 1999-06-03
HUP0101469A2 (hu) 2001-10-28
TW505642B (en) 2002-10-11
IL136303A0 (en) 2001-05-20
HUP0101469A3 (en) 2003-01-28
US6486190B1 (en) 2002-11-26
SK7792000A3 (en) 2001-01-18
CO4970802A1 (es) 2000-11-07
JP2001524478A (ja) 2001-12-04
EP1037887B1 (fr) 2004-07-14
ATE271048T1 (de) 2004-07-15
CN1284073A (zh) 2001-02-14
KR20010032435A (ko) 2001-04-25
EP1037887A1 (fr) 2000-09-27
NO20002655L (no) 2000-07-24
PL340711A1 (en) 2001-02-26
DE69825075D1 (de) 2004-08-19
NO20002655D0 (no) 2000-05-24
PE133699A1 (es) 2000-03-05
IL136303A (en) 2004-02-08
CA2311344C (fr) 2006-02-07
NZ504707A (en) 2002-11-26
ES2223143T3 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
US6117871A (en) 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
US6395764B1 (en) 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agnonists
AU730369B2 (en) Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists
US5965595A (en) 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US5804587A (en) 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists
EP1037887B1 (fr) 5-(2-imidazolinylamino)-benzimidazole, derives et procedes de preparation et d&#39;utilisation de ces derniers en tant qu&#39;agonistes du recepteur alpha-adrenergique ayant une meilleure stabilite metabolique
US6423724B1 (en) 7-(2-imidazolinylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
AU736992B2 (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists
US5914342A (en) 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists
US6436978B1 (en) Guanidinylamino heterocycle compounds useful as α-2 adrenoceptor agonists
CA2272098C (fr) Composes heterocycliques guanidinylamino utiles en tant qu&#39;agonistes de l&#39;adrenorecepteur alpha-2
EP0975627A1 (fr) Composes de 5-(2-imidazolinylamino)benzimidazole utiles en tant qu&#39;agonistes de l&#39;adrenorecepteur alpha-2
AU741774B2 (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
AU5433998A (en) 2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonis ts
WO1998023612A1 (fr) Composes 2-imidazolinylaminobenzothiazole utiles en tant qu&#39;agonistes de l&#39;adrenorecepteur alpha-2
MXPA00005120A (en) 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha. -adrenoceptor agonists with improved metabolic stability
CZ20001912A3 (cs) 5-(2-Imidazolinylamino)-benzimidazolové deriváty, jejich příprava a jejich použití jako alfa adrenoceptorové agonisty se zlepšenou metabolickou stálostí

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 136303

Country of ref document: IL

Ref document number: 98813286.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09554698

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 522100

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 504707

Country of ref document: NZ

Ref document number: 15299/99

Country of ref document: AU

Ref document number: 1200000476

Country of ref document: VN

ENP Entry into the national phase

Ref document number: 2311344

Country of ref document: CA

Ref document number: 2311344

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PV2000-1912

Country of ref document: CZ

Ref document number: 7792000

Country of ref document: SK

Ref document number: PA/a/2000/005120

Country of ref document: MX

Ref document number: 1020007005675

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998959512

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2000/02242

Country of ref document: TR

AK Designated states

Kind code of ref document: C1

Designated state(s): AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CU CZ CZ DE DE DK DK EE EE ES FI FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
WWP Wipo information: published in national office

Ref document number: 1998959512

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2000-1912

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007005675

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 15299/99

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007005675

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998959512

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-1912

Country of ref document: CZ